Improving thromboprophylaxis in elderly patients with non-valvular atrial fibrillation

Scottish Medical Journal

Volumn 49, Issue 4, 2004, Pages 148-150

  Lowdon, D W ^a   Harper, J R ^a   Gillespie, N D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Atrial fibrillation; Audit; Elderly; Guidelines; Stroke prevention; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; CHI SQUARE TEST; CONTROLLED STUDY; DRUG USE; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HOSPITAL DEPARTMENT; HOSPITAL DISCHARGE; HOSPITAL MANAGEMENT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MEDICAL RECORD; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; STATISTICAL SIGNIFICANCE; STROKE; THROMBOSIS PREVENTION;

EID: 11344265890     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1177/003693300404900411     Document Type: Review

References (16)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart R. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155: 469-73.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154:1449-57.
4. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158:1316-20.
5. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501.
6. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352:1167-71.
7. Smith NL, Psaty BM, Furberg CD, et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 1999; 159:1574-8.
8. Scottish Intercollegiate Guideline Network. Antithrombotic Therapy. Publication no. 36. Edinburgh, Royal College of Physicians, 1999.
9. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if efficacy of anticoagulation for stroke prevention in atrial fibrillation trials translates into clinical effectiveness. Br Med J 2000; 320: 1236-9.
10. Caro JJ, Flegel KM, Orejuela M, et al. Anticoagulation prophylaxis against stroke in atrial fibrillation: effectiveness in actual practise. CMAJ 1999; 161: 493-7
11. Atrial Fibrillation Investigators. Risk factors for stroke and the efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-57.
12. Aronow WS, Ahn C, Kronzon I, Gutstein H. Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. JAGS 1999; 47: 366-8
13. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk of falls. Arch Intern Med 1999; 159: 677-85
14. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-46
15. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-46
16. Stroke Prevention in Atrial Fibrillation III study. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Lancet 1996; 348: 633-38